Skip to main content
. 2020 Dec 11;55(Suppl 1):181–714. doi: 10.1038/s41409-020-01120-w
All Patients (101) BEAM (60) Mito-Mel (41)
Median Follow-up (months) 24 44 14
5 year PFS %63 %61 %74
5 year OS %70 %69 %75